SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lee WR,Moughan J,Owen JB,Zelefsky MJ. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer. 2003; 98: 19871994.
  • 2
    Mettlin CJ,Murphy GP,McDonald CJ,Menck HR. The National Cancer Data base report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer. 1999; 86: 18771882.
  • 3
    Lee WR,Sharkey J,Cowan JE,DuChane J,Carroll PR. Factors influencing prostate brachytherapy treatment and isotope choice for men with prostate cancer: a descriptive analysis from CaPSURE. Brachytherapy. In press.
  • 4
    Critz FA,Levinson K. Ten-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol. 2004; 172(6 pt 1): 22322238.
  • 5
    Dattoli M,Wallner K,True L,Cash J,Sorace R. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase. Cancer. 2003; 97: 979983.
  • 6
    Merrick GS,Butler WM,Wallner KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005; 61: 3243.
  • 7
    Potters L,Morgenstern C,Calugaru E, et al. Twelve-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005; 173: 15621566.
  • 8
    Stock RG,Cahlon O,Cesaretti JA,Kollmeier MA,Stone NN. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 59: 13521359.
  • 9
    Sylvester JE,Blasko JC,Grimm PD,Meier R,Malmgren JA. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys. 2003; 57: 944952.
  • 10
    Gelblum DY,Potters L,Ashley R,Waldbaum R,Wang XH,Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999; 45: 5967.
  • 11
    Gelblum DY,Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 48: 119124.
  • 12
    Ghaly M,Wallner K,Merrick G, et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys. 2003; 55: 12881293.
  • 13
    Albert M,Tempany CM,Schultz D, et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer. 2003; 98: 949954.
  • 14
    Kang SK,Chou RH,Dodge RK, et al. Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002; 53: 99103.
  • 15
    Sarosdy MF. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer. 2004; 101: 754760.
  • 16
    Lee WR,DeSilvio M,Lawton C, et al. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys. 2006; 64: 804809.
  • 17
    [No authors listed.] Consensus statement: guidelines for PSA following radiation therapy.American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997; 37: 10351041.
  • 18
    Roach MIII,Hanks G,Thames HJr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965974.
  • 19
    Kalbfleish JD. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons; 1980.
  • 20
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 21
    Eifel PJ,Levenback C,Wharton JT,Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995; 32: 12891300.
  • 22
    Michalski JM,Purdy JA,Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 2000; 46: 391402.
  • 23
    Michalski JM,Winter K,Purdy JA, et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003; 56: 192198.
  • 24
    Michalski JM,Winter K,Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys. 2004; 58: 735742.
  • 25
    Michalski JM,Winter K,Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys. 2005; 62: 706713.
  • 26
    Ryu JK,Winter K,Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002; 54: 10361046.
  • 27
    Zietman AL,Desilvio ML,Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294: 12331239.
  • 28
    Lawton CA,Desilvio ML,Lee WR, et al. Results of a phase II trial of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys. 2007; 67: 3947.
  • 29
    Wallner K,Merrick G,Sutlief S,True L,Butler W. High-dose regions versus likelihood of cure after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005; 62: 170174.
  • 30
    Crook JM,Potters L,Stock RG,Zelefsky MJ. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. Brachytherapy. 2005; 4: 186194.
  • 31
    Zelefsky MJ,Chan H,Hunt M,Yamada Y,Shippy AM,Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176: 14151419.
  • 32
    Peeters ST,Heemsbergen WD,Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24: 19901996.
  • 33
    Pollack A,Zagars GK,Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53: 10971105.